相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070
S. Dong et al.
LEUKEMIA (2008)
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells
V. Papa et al.
LEUKEMIA (2008)
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
A. Pardanani
LEUKEMIA (2008)
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
Jerome Tamburini et al.
BLOOD (2008)
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Jorge Cortes et al.
BLOOD (2007)
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential
Piu Wong et al.
GENES & DEVELOPMENT (2007)
ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia
M. H. G. P. Raaijmakers
LEUKEMIA (2007)
Crystal structure of the T315l Abl mutant in complex with the aurora kinases inhibitor PHA-739358
Michele Modugno et al.
CANCER RESEARCH (2007)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P. Shah et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia
J-H Mikesch et al.
LEUKEMIA (2007)
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis
N. Hosen et al.
LEUKEMIA (2007)
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells
Cong Peng et al.
BLOOD (2007)
Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential
A. M. S. Cheung et al.
LEUKEMIA (2007)
ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia
Chiara Gregorj et al.
BLOOD (2007)
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia
Jean-Luc Harousseau et al.
BLOOD (2007)
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
Arghya Ray et al.
BLOOD (2007)
A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis
B. Bellosillo et al.
LEUKEMIA (2007)
Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature
K. Nishii et al.
LEUKEMIA (2007)
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma
G. Metzgeroth et al.
LEUKEMIA (2007)
Essential thrombocythemia in young individuals:: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients
A. Alvarez-Larran et al.
LEUKEMIA (2007)
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells
C. Brendel et al.
LEUKEMIA (2007)
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells
Xiaoyan Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825
Tri K. Nguyen et al.
BLOOD (2007)
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies
X. Jiang et al.
LEUKEMIA (2007)
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
Zhihong Zeng et al.
BLOOD (2007)
FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells
B. Crescenzi et al.
LEUKEMIA (2007)
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis
Michele Milella et al.
BLOOD (2007)
Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines
D. J. Barnes et al.
LEUKEMIA (2007)
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Jeffrey E. Lancet et al.
BLOOD (2007)
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines
Antoinette Hollestelle et al.
MOLECULAR CANCER RESEARCH (2007)
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML):: biologic and clinical features
Brunangelo Falini et al.
BLOOD (2007)
Opportunities and obstacles to combination targeted therapy in renal cell cancer
Jeffrey A. Sosman et al.
CLINICAL CANCER RESEARCH (2007)
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells
Yoko Tabe et al.
CANCER RESEARCH (2007)
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Francis J. Giles et al.
BLOOD (2007)
JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/AML1-ETO-positive AML
S. Schnittger et al.
LEUKEMIA (2007)
Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia
M. Pocaly et al.
LEUKEMIA (2007)
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib
D. W. Sherbenou et al.
LEUKEMIA (2007)
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts
P. L. Tazzari et al.
LEUKEMIA (2007)
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
E. Jost et al.
LEUKEMIA (2007)
Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells
B. Zhang et al.
LEUKEMIA (2007)
JAK2 V617F due to a novel TG -> CT mutation at nucleotides 1848-1849: diagnostic implication
C. L. P. Wong et al.
LEUKEMIA (2007)
Reply to 'Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation' by Dr Ronald S Go
M. Inami et al.
LEUKEMIA (2007)
Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells
H. Gal et al.
LEUKEMIA (2006)
JAK2V617F mutational frequency in polycythemia vera:: 100%, > 90%, less?
S. Verstovsek et al.
LEUKEMIA (2006)
Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells
Ulrich Steidl et al.
NATURE GENETICS (2006)
Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5) (q13q33) myelodysplastic syndrome
R. A. Mesa et al.
LEUKEMIA (2006)
Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA
W. Ma et al.
LEUKEMIA (2006)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
The JAK2 V617F mutation is rare in RARS but common in RARS-T
M. M. Ceesay et al.
LEUKEMIA (2006)
Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche?
Aleksandra Rizo et al.
HUMAN MOLECULAR GENETICS (2006)
Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia
E. Tagliafico et al.
LEUKEMIA (2006)
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications
Ingo Roeder et al.
NATURE MEDICINE (2006)
Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia
R. A. Mesa et al.
LEUKEMIA (2006)
Understanding hematopoietic stem-cell microenvironments
Zhixing Li et al.
TRENDS IN BIOCHEMICAL SCIENCES (2006)
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E. Jabbour et al.
LEUKEMIA (2006)
Screening of JAK2 V617F mutation in multiple myeloma
A. Fiorini et al.
LEUKEMIA (2006)
JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients
L. Florensa et al.
LEUKEMIA (2006)
A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders
M. Di Ianni et al.
LEUKEMIA (2006)
Gene expression signatures associated with the resistance to imatinib
Y-J Chung et al.
LEUKEMIA (2006)
JAK2 mutation in a boy with polycythemia vera, but not in other pediatric hematologic disorders
M-J Park et al.
LEUKEMIA (2006)
Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia
M. Meier et al.
LEUKEMIA (2006)
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia
Kensuke Kojima et al.
BLOOD (2006)
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients
O. Frank et al.
LEUKEMIA (2006)
Proteasome inhibitor bortezomib for the treatment of multiple myeloma
M. Cavo
LEUKEMIA (2006)
Expression of β-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis
L. Ysebaert et al.
LEUKEMIA (2006)
Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells
F. E. Bertrand et al.
LEUKEMIA (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis
Paolo Lunghi et al.
BLOOD (2006)
BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry
A. Hamilton et al.
LEUKEMIA (2006)
A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis
A. M. Vannucchi et al.
LEUKEMIA (2006)
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained
D. P. Steensma et al.
LEUKEMIA (2006)
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients:: a retrospective analysis from the French intergroup of CML (Fi(φ)-LMC GROUP)
F. E. Nicolini et al.
LEUKEMIA (2006)
Gene expression profiling of CD34+cells identifies a molecular signature of chronic myeloid leukemia blast crisis
C. Zheng et al.
LEUKEMIA (2006)
Activation of FGFR1β signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells
M. A. Karajannis et al.
LEUKEMIA (2006)
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Teru Hideshima et al.
BLOOD (2006)
Implications of NRAS mutations in AML:: a study of 2502 patients
Ulrike Bacher et al.
BLOOD (2006)
JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders
B Bellosillo et al.
LEUKEMIA (2006)
The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib
C Miething et al.
LEUKEMIA (2006)
JAK2 V617F mutation in classic chronic myeloproliferative diseases:: a report on a series of 349 patients
JL Vizmanos et al.
LEUKEMIA (2006)
KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21):: a study of the Japanese Childhood AML Cooperative Study Group
A Shimada et al.
BLOOD (2006)
Signalling responses linked to betulinic acid-induced apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid melanoma irrespective of p53 status
M Rieber et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia
D Rea et al.
LEUKEMIA (2006)
Activating mutations of JAK2V617F are uncommon in t-MDS and t-AML and are only observed in atypic cases
F Desta et al.
LEUKEMIA (2006)
Implications of the expression of myeloid markers on normal and leukemic stem cells
DJ Pearce et al.
CELL CYCLE (2006)
Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia
CP Kratz et al.
LEUKEMIA (2006)
Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis
C James et al.
LEUKEMIA (2006)
Chronic myeloproliferative disorders: a tyrosine kinase tale
K De Keersmaecker et al.
LEUKEMIA (2006)
Eradication of leukemia stem cells as a new goal of therapy in leukemia
F Ravandi et al.
CLINICAL CANCER RESEARCH (2006)
Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders
R McClure et al.
LEUKEMIA (2006)
Absence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma
I Melzner et al.
LEUKEMIA (2006)
Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML
A Hiramatsu et al.
LEUKEMIA & LYMPHOMA (2006)
The NF-kappa B pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance
D Cilloni et al.
LEUKEMIA (2006)
The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis
SF Yip et al.
LEUKEMIA (2006)
t(5;12)(q23-31;p13) with ETV6-ACSL6 gene fusion in polycythemia vera
A. Murati et al.
LEUKEMIA (2006)
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia
A. M. Martelli et al.
LEUKEMIA (2006)
Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome
C-Y Chen et al.
LEUKEMIA (2006)
The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients
K Ohyashiki et al.
LEUKEMIA (2005)
Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia
DH Christiansen et al.
LEUKEMIA (2005)
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
K Kojima et al.
BLOOD (2005)
A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib
LC Crossman et al.
LEUKEMIA (2005)
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
E Antonioli et al.
LEUKEMIA (2005)
Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia:: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
S Amadori et al.
LEUKEMIA (2005)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
SY Sun et al.
CANCER RESEARCH (2005)
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells
M Levis et al.
BLOOD (2005)
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells
KC Zhu et al.
BLOOD (2005)
Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2)
M Rolfe et al.
BIOCHEMICAL JOURNAL (2005)
Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway
C Yu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo
Y Luo et al.
MOLECULAR CANCER THERAPEUTICS (2005)
The p53 pathway: positive and negative feedback loops
SL Harris et al.
ONCOGENE (2005)
Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity
LM Hawkins et al.
PEDIATRIC RESEARCH (2005)
Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK
Y Dai et al.
BLOOD (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells
P Lunghi et al.
LEUKEMIA (2005)
Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects
M Milella et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
Targeting the bone marrow microenvironment in hematologic malignancies
WS Dalton et al.
SEMINARS IN HEMATOLOGY (2004)
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias
S Zhao et al.
LEUKEMIA (2004)
Altered states: selectively drugging the Hsp90 cancer chaperone
P Workman
TRENDS IN MOLECULAR MEDICINE (2004)
Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia
PB Staber et al.
ONCOGENE (2004)
Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling
N Vey et al.
ONCOGENE (2004)
The complexity of PTEN: mutation, marker and potential target for therapeutic intervention
LS Steelman et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2004)
Constitutive NF-kappa B DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway
KU Birkenkamp et al.
LEUKEMIA (2004)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation
JG Shelton et al.
LEUKEMIA (2003)
Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia
T Matsunaga et al.
NATURE MEDICINE (2003)
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia
S Meshinchi et al.
BLOOD (2003)
Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia
WL Blalock et al.
LEUKEMIA (2003)
Temporal gene expression profile of human precursor B leukemia cells induced by adhesion receptor: identification of pathways regulating B-cell survival
AL Astier et al.
BLOOD (2003)
Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice
JH Black et al.
LEUKEMIA (2003)
Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571
R Nimmanapalli et al.
ONCOGENE (2002)
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism
Y Dai et al.
BLOOD (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory
C Mazzucchelli et al.
NEURON (2002)
Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs
MV Blagosklonny
LEUKEMIA (2002)
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
M Milella et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Discovery of a novel Raf kinase inhibitor
JF Lyons et al.
ENDOCRINE-RELATED CANCER (2001)
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia
GG Wulf et al.
BLOOD (2001)
p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD
H Harada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Novel role for JNK as a stress-activated Bcl2 kinase
XM Deng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
CT Jordan et al.
LEUKEMIA (2000)
Recent approaches in acute lymphoblastic leukemia in adults
D Hoelzer et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2000)
Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias
AE Frankel et al.
LEUKEMIA (2000)
分享论文
